2022 CURESEARCH PEDIATRIC EARLY DEVELOPMENT SYMPOSIUM
PEDS 2022 registration will open July 13. A Working Group convened by CureSearch that integrates leaders in industry, academia and regulatory is currently developing the agenda. If you would like to be kept up-to-date on our progress, please let us know.
About the Symposium
Launched in 2020 in response to the passage of Title V of the FDA Reauthorization Act, commonly known as the RACE for Children Act, the CureSearch Pediatric Early Development Symposium (PEDS) serves as an opportunity for industry, academia and regulatory leaders to examine the dynamic nature of clinical trials for a super rare population - children with cancer.
Each subsequent PEDS has built upon the last, returning participants to a mindset of advancing pediatric cancer clinical trials and exploring resources, infrastructure, collaborations and – in 2022 – technological integrations that make clinical trials for rare patient populations more robust and efficient.
PEDS 2022: Leveraging Big Data to Advance Pediatric Clinical Trials
Big data technology is revolutionizing every aspect of our lives and healthcare is no different. Important efforts for improving clinical trials – especially in diseases with small patient populations – include global coordination, integration of innovations like decentralized infrastructure, real-world evidence and external controls. The only way to effectively coordinate and implement these strategies effectively is to engage technology in new ways. The 2022 PEDS will explore global technological efforts to improve clinical trial design and implementation. Using a robust interactive virtual platform, participants will be encouraged to discuss challenges and propose solutions to technology integration within their work and brainstorm opportunities to craft the future of clinical trials.
Jeffrey Skolnik, MD
Brenda Weigel, MD
Director of the Division of Pediatric Hematology/Oncology
University of Minnesota's Masonic Cancer Center
Working Group Members
Industry leaders, academics and other thought leaders in pediatric drug development including:
Research and Development
Academic/Key Opinion Leaders